Aims Total bilirubin tests are individually inexpensive but can result in huge costs to healthcare systems worldwide, because they are very commonly requested. The main objective of this study was to evaluate the diagnostic accuracy of the icteric index, a test with zero reagent cost, as a preliminary biomarker to decide when total bilirubin measurement is necessary. Methods We retrospectively reviewed all the requested total bilirubin values and their corresponding icteric index results in a 2-year period (2010e11). Receiver operating characteristic (ROC) curve analysis was used to determine the optimal icteric index cut-off value to discriminate between normal and abnormal bilirubin values (>20.5 mmol/l; >1.2 mg/dl). Results The study included total bilirubin and icteric index results of 100 207 patients. The ROC curve analysis suggested 34.2 mmol/l (2 mg/dl) as the optimal icteric index threshold to identify abnormal bilirubin values. The area under the curve was 0.981. Regardless of the patient population studied (primary care, hospital and different individual hospital departments), sensitivity was greater than 94% and specificity was over 98%. Likelihood ratio values provided strong evidence that total bilirubin is less than 20.5 mmol/l (<1.2 mg/dl) when the icteric index is less than 34.2 mmol/l (<2 mg/dl). Conclusions This study supports the use of the icteric index to identify patients with abnormal total bilirubin values. Considerable economic savings can be achieved if this strategy is applied on a clinical daily basis. Its implementation and report should be discussed and planned by laboratory professionals together with requesting physicians.
INTRODUCTION
The icteric index, 1 defined as a quantification of bilirubin or 'icterus' interference, is currently measured in most of the chemistry analysers at 'zero reagent cost'. The analyser takes an aliquot of the patient specimen and dilutes it in saline to measure the absorbance for icterus, for lipaemia and for haemolysis. From these absorbance values, the instrument calculates the serum icteric index using factors, providing a semiquantitative representation of levels of icterus present in serum samples. The icteric index, as well as lipaemic and haemolitic indices, can currently be measured before chemistry test quantification, to detect possible sample interferences, and support correct laboratory test verification and reporting.
Total bilirubin request rates are high despite the fact that its use as a screening test for chronic liver disease in the general population is not cost effective. 2 Indeed, bilirubin values are normal in essentially all patients, 3 and the request for this test should be limited to high-risk individuals. 4 Serum alanine aminotransferase is, currently, the preferred screening liver marker because it peaks sooner than bilirubin. 5 Despite this fact, total bilirubin is still over-requested. 6 In this scenario, laboratory professionals should establish the appropriate measures to achieve maximal laboratory efficiency in clinical decisionmaking at the lower cost. Strategies to achieve appropriate test requesting are difficult to establish. 7 Some of them, such as educative tests, are complicated to maintain over time. 8 Effective interventions, ie, the modification of the request form, 9 10 are difficult to set up now due to electronic requesting technology that in some cases cannot modify the test demand. 11 This renders the search for other specific and systematic interventions mandatory. 12 It has been shown that the icteric index should not be used for the quantitative determination of total bilirubin. 1 However, its use as a semiquantitative icteric test to detect abnormal total bilirubin values and to decide whether its quantification is worthwhile has not yet been evaluated.
The aim of our work was to study whether the icteric index can be used as a preliminary biomarker to decide when total bilirubin measurement is necessary, when requested. For this purpose, we first analysed the diagnostic accuracy of the test for differentiating between normal and pathological total bilirubin values. Then we studied the economic effects of its implementation. Finally, we discuss how this new intervention can be explained to requesting physicians and how icteric index and total bilirubin results can be reported on a daily clinical basis.
MATERIALS AND METHODS Study design
The laboratory is located at the University Hospital of San Juan (Alicante, Spain), a 370-bed suburban community hospital that serves a population of 234 551 inhabitants. It has been certified to ISO 9001 standard since 2004. In 2010 and 2011, 4 781 000 chemistry tests were performed.
We retrospectively reviewed all the values of total bilirubin requested and their corresponding icteric index results between January 2010 and December 2011. Both test results were obtained from the laboratory database (OMEGA 3000; Roche Diagnostics (Barcelona, Spain)) through data warehouse-based software (OMNIUM; SunSet Technologies (Girona, Spain)). To evaluate the previous results in a different analyser a prospective 2-month study (December 2011 and January 2012) was performed in the stat laboratory (481 409 chemistry tests performed in year 2011) in a separate population, using a different technology.
The STARD statement was used to ensure that all relevant information is present in the study. 13 
Total bilirubin and icteric index measurements
The total bilirubin concentration was measured using a Cobas c 711 (CE marked and US Food and Drug Administration (FDA) evaluated test; Roche Diagnostics (Barcelona, Spain)) in which nearly 900 requests with over seven tests per request are processed daily, in serum samples. The analyser employed a colorimetric assay. The intended use of bilirubin, as stated in the analyser instructions, is an in-vitro test for the quantitative determination of total bilirubin in human serum and plasma. In the presence of a suitable solubilising agent, total bilirubin is coupled with a diazonium ion in a strongly acidic medium to produce azobilirubin. The colour intensity (measured at 600/ 546 nm) of the red azo dye formed is directly proportional to the total bilirubin.
The icteric index was also measured in a Cobas c711. It is a CE marked test but does not have FDA approval. Its calculation is based on calculations of absorbance measurements of diluted samples at different bichromatic wavelength pairs that provide a semiquantitative representation of levels of icterus present in serum. The analysers take an aliquot of the patient specimen and dilute it in saline (0.9% sodium chloride) to measure the absorbances for lipaemia at 660 nm (primary wavelength) and 700 nm (secondary wavelength), for haemolysis at 570 nm (primary wavelength) and 600 nm (secondary wavelength), and for icterus at 480 nm (primary wavelength) and 505 nm (secondary wavelength). From these absorbance values the instrument calculates serum index values using the formula shown in box 1. The values are independent of sample dilution as they are based on ratios of absorbances. There should not be any discordance based on the bilirubin conjugation status. The icteric index is calibrated to total bilirubin. The intended use of the icteric index, as stated by the company instructions for use, is an in-vitro test for the semiquantitative determination of the icterus index in human serum and plasma.
For the Cobas analyser, the within-lab coefficients of variation (CV) for total serum bilirubin were 1.9% and 0.6% at 17.4 mmol/ l (1.02 mg/dl) and 86.2 mmol/l (5.04 mg/dl), respectively; the within-lab CV for the serum icteric index was less than 0.1% at 17.1 mmol/l (1 mg/dl) and at 34.2 mmol/l (2 mg/dl).
In the stat laboratory, total bilirubin and icteric index were measured using a Dimension RxL Max (Siemens Healthcare Diagnostics, Barcelona, Spain). Both tests are CE marked, and total bilirubin is FDA approved. Bilirubin, on the addition of the diazotised sulfanilic acid is converted to diazo-bilirubin, which absorbs at 540 nm and is measured using a bichromatic (540, 700 nm) endpoint technique. The icteric index calculation is based on calculations of absorbance measurements at 452 and 700 nm. The Dimension system automatically converts absorbance measurements to icteric index values corresponding to the approximate concentration ranges. The within-lab CV for total serum bilirubin were 2.7% and 1% at 14 mmol/l (0.84 mg/dl) and 74 mmol/l (4.3 mg/dl), respectively; the within-lab CV for the serum icteric index was less than 0.1% at 17.1 mmol/l (1 mg/dl) and at 34.2 mmol/l (2 mg/dl).
Total bilirubin in both analysers presented acceptable internal quality control and external quality assurance. Actually there is no external quality assurance for the icteric index.
Statistical analysis
We compared icteric index and total bilirubin test results. The latter was considered the gold standard. Linear regression analysis was performed, and the correlation coefficient was calculated. Receiver operating characteristic (ROC) curve analysis was used to determine the optimal icteric index cut-off value (by maximising the sum of sensitivity and specificity) to discriminate between patients with normal and abnormal bilirubin values. Bilirubin values were considered abnormal when they were above 20.5 mmol/l (1.2 mg/dl). 14 We calculated sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) and likelihood ratios for positive (LR+) and negative (LRÀ) results. Data are presented with exact 95% CI. All parameters were calculated for the whole population and for different subgroups according to patient derivation (primary care, hospital inpatients and outpatients and different individual hospital departments). The analysis was performed using SPSS for Windows V.11.0.
RESULTS
The study included 100 207 patients' total bilirubin and icteric index results during the years 2010 and 2011. Each of the 100 207 patients had only one bilirubin result. The mean age of the study population was 55 years (range 0e111 years) and 45.3% of participants were men. Patient characteristics are presented in table 1 .
A graph of the icteric index versus total bilirubin concentration and regression data are shown in figure 1. The correlation coefficient (R 2 ) of total bilirubin and the icteric index was 0.891. The ROC curve analysis for the whole population (figure 2) suggested that the most accurate icteric index cut-off value to differentiate bilirubin values above and below 20.5 mmol/l (1.2 mg/dl) was 34.2 mmol/l (2 mg/dl). The area under the curve was 0.981. The sensitivity, specificity, PPV, NPV, LR+ and LRÀ of the icteric index for the detection of total bilirubin values Regardless of the patient population studied, sensitivity was greater than 94% and specificity was greater than 98%. LR values provided strong evidence that the bilirubin value is under 20.5 mmol/l (1.2 mg/dl) when the icteric index result is under 34.2 mmol/l (2 mg/dl). In the whole population there were 4499 truly positives, 94 303 truly negatives, and the number of false results was minimal, with 1241 (1.2%) false positives and 164 (0.16%) false negatives. Analysis of false negative results ( figure 3) showed a mean total bilirubin of 21.7 mmol/l (1.27 mg/dl) (95% CI 21.5 to 21.9 mmol/l) (1.26 to 1.28 mg/dl)). False positive results showed a mean total bilirubin of 17.6 mmol/l (1.06 mg/dl) (95% CI 18.1 to 18.3 mmol/l) (1.06 to 1.07 mg/dl).
Box 1 Equation for calculating the icteric index in Cobas c711
The icteric index cut-off for 100% sensitivity is 0 mmol/l (0 mg/dl) and for 100% specificity is 51.3 mmol/l (3 mg/dl).
Patient demographics and the sensitivity, specificity, PPV, NPV, LR+ and LRÀ values of the icteric index for the detection of total bilirubin values above 20.5 mmol/l (1.2 mg/dl) in the stat laboratory samples are shown in table 4. All the samples were handled according to the manufacturer 's recommendations.
We studied the economic effects of having applied the icteric index as a screening procedure. We would have saved 94 467 total bilirubin tests in the 2-year period. Considering a cost of V0.18 per determination of total bilirubin, the implementation of the icteric index would have saved V17 016.
DISCUSSION
This is the first study to show the value of the icteric index as a front-line semiquantitative test to decide on performing the measurement of total bilirubin when the latter is requested. The diagnostic accuracy results of our study show the excellent correlation between the icteric index and total bilirubin results. The icteric index is able to detect patients with total bilirubin values above the reference range.
14 This is the first application of the icteric index for diagnostic purposes. The icteric index may represent a valid and reliable test, and may give an important insight into clinical laboratory appropriateness in clinical decision-making.
Using a 34.2 mmol/l (2 mg/dl) icteric index cut-off value, the discrimination of patients with normal and abnormal bilirubin values was almost perfect. As a test to be used as a screening tool, the analysis of false negative cases is crucial. A separate analysis of the distribution of those results is shown in figure 3 . False negative cases were scarce. Interestingly, just four values were above 25.6 mmol/l (1.5 mg/dl), and no value was higher than 29 mmol/l (1.7 mg/dl). This supports the strength of the icteric index test as a screening tool with a great potential to obviate the need to measure total bilirubin when values are below the proposed cut-off. Therefore, we suggest the icteric index as a front-line diagnostic test. For values above 34.2 mmol/l (2 mg/dl), total bilirubin should be measured.
Some of the 1241 false positive results were probably caused by interference of other yellow pigments such as carotene or haemoglobin. However, as false positive results, bilirubin is still measured in those samples. As a consequence, in the case of haemolysis or a high carotene concentration, correct total bilirubin values are reported.
The accuracy of the icteric index was tested in different patient populations (primary care, hospital and different individual hospital departments), for which the total bilirubin test is usually requested for different purposes (either to rule out, to confirm or to follow up a disease), and is supposed to have different results (probably normal for primary care and possibly abnormal for oncology and gastroenterology patients). The study results showed a high ability to detect patients with abnormal results in every setting. Despite its excellent accuracy, given the high prevalence of jaundice in neonates, the icteric index strategy may not be necessary in this population.
The icteric index has several advantages: it is technically simple and fast to measure (less than 20 s); it lacks problems involving reagent presentation, preparation or stability; and the reagent cost is zero. Furthermore, if bilirubin test measurement is avoided, more sample will be available to process the other requested tests in the case of small specimens such as children's samples. Therefore, it can become the first election marker when a total bilirubin test is requested in every healthcare setting.
This index can be used as a screening tool to avoid total bilirubin measurement in a substantial number of cases. This is especially important in a patient population such as the one reported in our study for which, unfortunately, bilirubin is inappropriately requested as a screening test for chronic liver disease, as shown by the fact that 95% of the test values were in the reference range.
We have shown how this would have resulted in considerable economic savings if it had been routinely applied in the 2-year period of our study. Applying such an approach to primary care bilirubin requesting in a 1-year period in eight laboratories 6 serving 2 014 475 inhabitants in the Valencian community area, would have achieved a V35 976 saving. The implementation of this strategy for all primary care patients in Spaindnot taking into account outpatients and inpatientsdwould save approximately V1.14 million annually.
The total bilirubin test is individually inexpensive. However, like some other laboratory tests that are ordered daily on thousands of patients, it is a clear example of a 'little ticket' 15 healthcare procedure. Despite its individual low cost, because it is commonly requested, this test can result in huge costs to the healthcare system, even more than those related to other expensive diagnostic tests. 16 It is a duty of clinical laboratory professionals to improve the quality of patient care while trying to decrease the costs. Achieving an appropriate request of the 'little ticket' tests should be one of the main objectives. To define and implement laboratory strategies for continuous healthcare quality improvement, through modern business tools such as the balanced scorecard, 17 should be a daily professional laboratory task. Performing the icteric index measurement as a screening test when total bilirubin is requested not only reduces costs but improves the quality of the procedure, given its simplicity and quick response time.
Regarding what may be the best strategy to implement the use of the icteric index on a daily basis; we believe that the first step is to inform the requesting physicians about the excellent diagnostic accuracy of the index to differentiate between normal and abnormal total bilirubin values. In our opinion, the second step would be to reach a consensus about how results should be reported. As stated, the icteric index, a semiquantitative measurement, cannot replace the quantitative determination of total bilirubin. However, when the index is below 34.2 mmol/l (2 mg/dl), total bilirubin could be reported through a comment such as 'with a confidence interval of 99%, total bilirubin result is below 20.5 mmol/l (1.2 mg/dl)'. The implementation of the semiquantitative icteric test in clinical practice must be organised according to every individual laboratory's characteristics, and through communication to laboratory stockholders. The icteric index is a semiquantitative test, as it is not used for decision-making but to detect patients with total bilirubin values above the reference range, it can be safely utilised by laboratories.
The strengths of this study are that the icteric index was tested on all serum samples when total bilirubin was requested in a 2-year period, and that the sample size was large enough to give adequate power for area under the curve analysis in different patient populations. One limitation of our work may be related to the fact that the icteric index is not FDA approved and, as such, it may not be reimbursed by insurance companies in some countries. The variation regarding the reference interval of normal bilirubin values reported in the literature 14 18 could also represent a limitation for the generalisation of the results of our study. Yet, the major limitation of our work is that the study was performed in a single laboratory, using a single chemistry Table 2 Prediction of abnormal total bilirubin using a 34.2 mmol/l (2 mg/dl) icteric index threshold in the whole population and for inpatients, outpatients and primary care patients analyser. There is no standardisation and thus the Cobas icteric index may not have the same diagnostic index as icteric indexes calculated with other analysers. To try to solve this issue, we accomplished individual statistical analysis for different subgroups of patients and we performed a separate prospective analysis in a distinct patient population, using different technology. In any case, the findings of our study can be considered preliminary and should encourage other laboratories to validate the accuracy and effectiveness of the proposed approach, considering their own individual population and chemistry analysers. Future multicentre research is suggested to show that the icteric index is ready to be used in daily practice as a marker to select patients for total bilirubin calculation.
CONCLUSIONS
The present study supports the use of the icteric index to identify patients with abnormal total bilirubin values. Considerable economic savings can be achieved if this strategy is applied on a clinical daily basis. The strategy for icteric index implementation and report should be planned by laboratory professionals, discussed with requesting physicians, according to specific laboratory characteristics.
What this paper adds
< It has been shown that the icteric index should not be used for the quantitative determination of total bilirubin. However, its use as a semiquantitative icteric test to detect abnormal total bilirubin values and to decide whether its quantification is worthwhile has not yet been evaluated. < This is the first study that shows the value of the icteric index as a front-line semiquantitative test to decide on performing the measurement of total bilirubin when the latter is requested. The diagnostic accuracy results of our study show the excellent correlation between the icteric index and total bilirubin results. The icteric index is able to detect patients with total bilirubin values above the reference range.
Take-home messages < The aim of our work was to study whether the icteric index can be used as a preliminary biomarker to decide when total bilirubin measurement is necessary, when requested. < This is the first study that shows the value of the icteric index as a front-line semiquantitative test to decide on performing the measurement of total bilirubin, when the latter is requested. < The present study supports the use of the icteric index to identify patients with abnormal total bilirubin values. Considerable economic savings can be achieved if this strategy is applied on a clinical daily basis. 
